Surgical Drapes and Gowns Market: as the AAMI PB70 barrier performance standard now rates a broader range of protective apparel categories than its prior edition covered, hospital purchasing has a genuinely finer-grained basis for distinguishing premium barrier products from standard ones, so the category is bifurcating between a commoditised standard-barrier segment where low-cost Asian manufacturers compete almost entirely on price and a smaller but growing premium segment where AAMI-rated barrier performance claims still command a defensible price premium.

The global surgical drapes and gowns market size was USD 4.69 Billion in 2025 and is expected to register a revenue CAGR of 5.1% during the forecast period. Market revenue growth is driven by factors such as rising surgical procedure volumes globally sustaining structural demand for sterile surgical apparel, healthcare-associated infection prevention mandates under the AAMI PB70 barrier performance standard expanding premium disposable product adoption, and continued expansion of the standard’s rated protective apparel categories giving hospital procurement a finer basis for distinguishing premium from standard barrier products. The first driving factor is rising surgical procedure volumes globally, sustaining structural demand for the sterile drapes and gowns that every surgical procedure requires to maintain a sterile field. Every surgical procedure requires both a sterile drape system to establish the sterile field around the surgical site and surgical gowns for the operating team, establishing a direct mechanical link between global surgical procedure volume and drape and gown consumption. The second driving factor is healthcare-associated infection prevention mandates under the AAMI PB70 barrier performance standard, expanding premium disposable drape and gown adoption at acute care hospitals prioritising demonstrated barrier protection. The current edition of ANSI/AAMI PB70 established four classification levels of barrier performance for surgical gowns, isolation gowns, and surgical drapes, giving hospital infection prevention teams an objective, standardised basis for selecting appropriate protective apparel by clinical risk level. The third driving factor is the standard’s expanded rated protective apparel categories, extending barrier performance classification and labelling to product types, including decontamination and procedure gowns, that previously carried no formal barrier rating. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way an objective, standardised barrier performance classification system widens the addressable premium product market by giving hospital procurement committees a defensible, auditable basis for paying more for a higher-rated product rather than defaulting to whichever compliant option costs least. Once a barrier performance classification system assigns an objective, testable rating to a drape or gown, a hospital infection prevention team can justify a premium purchase decision to procurement and finance stakeholders by pointing to the specific, standardised classification level required for a given procedure’s clinical risk, rather than needing to argue for a premium product on manufacturer marketing claims alone, so the existence of an objective rating system and defensible premium product purchasing are directly linked. As a result, demand and revenue share are concentrating around manufacturers with clearly AAMI-rated, well-documented barrier performance claims for their premium product lines, and the forecast tilts toward this documented-premium segment capturing a larger share of category value growth rather than the broader market commoditising uniformly across all barrier levels. For instance, the current edition of ANSI/AAMI PB70 extended formal barrier performance classification and labelling to additional protective apparel categories, including decontamination and procedure gowns, that previously carried no rated barrier claim, giving hospital procurement a finer-grained, standard-referenced basis for premium product selection across a broader range of product categories than the prior edition supported. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the direct, mechanical relationship between global surgical procedure volume and surgical drape and gown consumption, since every surgical procedure requires both a sterile drape system and gowns for the operating team. A surgical procedure cannot proceed without establishing a sterile field around the surgical site and protecting the operating team from fluid exposure, and drapes and gowns are the products that serve these two functions in virtually every procedure regardless of specialty, so surgical procedure volume growth and drape and gown unit demand growth are directly and mechanically linked. Global surgical procedure volume continues to grow steadily across both developed and emerging healthcare markets, sustaining structural demand for the sterile surgical apparel every procedure requires. The effect on the market is that surgical drape and gown unit demand growth tracks underlying surgical procedure volume growth relatively closely, even where value growth lags in the commoditised standard-barrier segment. These are some of the key factors driving revenue growth of the market.

The second driver is the existence of an objective, testable barrier performance classification system that hospital infection prevention teams can reference when justifying a premium product purchase for higher-risk procedures. A hospital procurement decision defaulting purely to unverified manufacturer marketing claims faces internal resistance from finance stakeholders focused on cost, while a decision grounded in an objective, standardised classification level required for a specific procedure’s clinical risk carries a defensible rationale that finance stakeholders can audit, and this defensibility is what allows infection prevention teams to secure budget for premium barrier products at the classification level a given procedure genuinely requires. The current edition of ANSI/AAMI PB70 established four classification levels of barrier performance, with Level 4 products demonstrating resistance to synthetic blood and blood-borne pathogen penetration under standardised laboratory test methods including ASTM F1670 and F1671. The recent record shows the pace. The current standard also extended formal barrier performance classification and labelling to decontamination and procedure gowns, product categories that previously carried no rated barrier claim under the prior edition. The effect on the market is that hospital procurement decisions for premium disposable drapes and gowns increasingly reference a specific, auditable AAMI classification level rather than depending on unverified manufacturer claims alone. These are some of the key factors driving revenue growth of the market.

“The current edition of ANSI/AAMI PB70 established four classification levels of barrier performance and extended formal rating coverage to decontamination and procedure gowns for the first time, giving hospital infection prevention teams an objective, auditable basis for premium disposable drape and gown purchasing decisions across a broader range of protective apparel categories than the prior standard supported.”

The third driver is the extension of barrier performance classification and labelling coverage to additional protective apparel categories beyond the traditional surgical gown, isolation gown, and surgical drape scope. A protective apparel category lacking any formal barrier rating leaves hospital purchasers unable to objectively compare barrier performance across competing products in that category, and extending classification coverage to previously unrated categories, including decontamination and procedure gowns, closes this comparability gap for a broader range of hospital protective apparel purchasing decisions. The current standard’s expanded scope allows non-surgical and non-isolation medical gowns, such as decontamination gowns and procedure gowns, to be formally rated for barrier protection for the first time. The effect on the market is that objective barrier performance comparison, and the premium purchasing decisions it supports, now extends to a broader range of hospital protective apparel categories than the prior standard edition covered. These are some of the key factors driving revenue growth of the market.

However, the surgical drapes and gowns market faces severe adoption constraints from sustained commoditisation pressure in the standard barrier product segment, low-cost Asian manufacturer competition constraining established Western suppliers even in differentiated categories, and group purchasing organisation contract consolidation reinforcing price as the primary competitive dimension across a large share of total category volume. Because standard barrier drape and gown performance has substantially standardised across compliant suppliers meeting recognised AAMI classification requirements at the lower barrier levels specifically, hospital procurement committees purchasing standard-tier products increasingly treat this segment as a price-and-reliability decision, limiting the pricing power any individual manufacturer can sustain across the largest-volume portion of total category purchasing. Low-cost Asian manufacturer competition compounds this, because manufacturers with efficient production scale continue to expand capacity and compete directly against established Western suppliers on price within the AAMI PB70 classification framework, and this competitive pressure extends into portions of the premium segment where procurement committees remain unwilling to pay a full premium even for documented higher-rated barrier performance, so the objective classification system alone does not guarantee pricing power without genuine procurement committee willingness to prioritise the rating over price. Group purchasing organisation contract consolidation is the third constraint, since large-scale hospital group purchasing organisation contracts concentrate substantial drape and gown procurement volume within a small number of contract awards, and this concentration further reinforces price as the primary competitive dimension in these contract award decisions, so manufacturers without genuinely differentiated, well-documented barrier performance struggle to sustain pricing power outside a narrow set of the highest-acuity procedure categories. These factors substantially limit surgical drapes and gowns market growth over the forecast period.

Based on product type, the global surgical drapes and gowns market is segmented into surgical drapes and surgical gowns. Surgical gowns hold the largest revenue share, because they represent the higher-value protective apparel category given their more complex construction and the broader range of AAMI PB70 classification levels manufacturers, including Cardinal Health and Medline, offer within the gown category specifically. Surgical drapes are expected to register a significantly large revenue share in the global surgical drapes and gowns market over the forecast period, reflecting their essential role in establishing the sterile field for every surgical procedure regardless of specialty.

Nonwoven (disposable) material is expected to account for the largest revenue share in the global surgical drapes and gowns market during the forecast period

Based on material, the global surgical drapes and gowns market is segmented into nonwoven (disposable) and woven (reusable) materials. Nonwoven material holds the largest revenue share, reflecting healthcare-associated infection prevention protocols’ continued preference for single-use protective apparel over reusable textile alternatives, particularly for higher AAMI classification level procedures. Woven (reusable) material represents a smaller, declining revenue category, retained primarily at facilities with established reusable textile processing infrastructure and cost sensitivity favouring the lower per-use cost reusable apparel can offer.

Disposable usability tier is expected to account for the largest revenue share in the global surgical drapes and gowns market during the forecast period

Based on usability, the global surgical drapes and gowns market is segmented into disposable and reusable products. Disposable products hold the largest revenue share, reflecting the broader industry-wide shift toward single-use protective apparel across acute care procurement channels. Reusable products are expected to register the fastest revenue growth rate in the global surgical drapes and gowns market over the forecast period in specific cost-sensitive and sustainability-focused hospital systems, driven by growing hospital sustainability initiatives, which is why this category represents a smaller but genuinely growing niche within the broader market.

Based on regional analysis, the surgical drapes and gowns market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of hospital sterile processing and surgical procedure volume globally, and because Cardinal Health and Medline both concentrate significant commercial activity in the country. The ANSI/AAMI PB70 barrier performance standard directly shapes United States hospital protective apparel procurement decisions, giving domestic infection prevention teams the classification framework this report’s central premiumisation dynamic depends on. The concentration of the largest surgical procedure volume base and leading drape and gown manufacturers in the United States also means new AAMI-rated product categories are typically launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national surgical drapes and gowns markets within Europe. The region’s CE-marking regulatory pathway under the Medical Device Regulation operates alongside, rather than identically to, the United States AAMI PB70 framework, creating some friction for manufacturers seeking to market identical barrier performance claims across both regions. The result is steady rather than rapid growth, shaped more by this regulatory framework divergence than by unmet clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national surgical drapes and gowns markets within the region. Expanding hospital infrastructure investment and rising surgical procedure volume in China and India are driving new demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national surgical drapes and gowns markets within the region. Hospital sterile processing departments in both countries continue gradually expanding capacity, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the nonwoven raw materials and finished surgical apparel that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial surgical drapes and gowns markets within the GCC. The UAE is the most established surgical drapes and gowns market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building the surgical infrastructure that drape and gown demand depends on.